Most uncommon mutations are between exons 18 to 21, and exon 20 insertions specifically represent 4%-12% of the EGFR alterations seen in EGFR-driven NSCLC.27 Patients with exon 20 insertions have limited benefit from standard EGFRm TKIs or immunotherapy and have more promising options with the FDA approvals of amivantamab and mobocertinib as 2L therapy.24,27 Better validation of uncommon EGFR mutations, understanding of clinical implications, and standardization of reporting is needed to aid treatment decisions. Here, EGFR is linked to non-small cell lung carcinoma.